Alliance of States with Prescription Monitoring Programs (ASPMP). (2007). An assessment of state prescription monitoring program effectiveness and results. Retrieved Sep. 11, 2012, from www.pmpexcellence.org/pdfs/alliance_pmp_rpt2_1107.pdf
Alliance of States with Prescription Monitoring Programs (ASPMP). (2010). Prescription Monitoring Program Model Act 2010 revision. Retrieved Feb. 26, 2012, from pmpalliance.org/pdf/PMPModelActFinal20100628.pdf
Baehren, D.F., Marco, C.A., Droz, D.E., Sinha, S., Callan, E.M., & Akpunonu P. (2010). A statewide prescription monitoring program affects emergency department prescribing behaviors. Annals of Emergency Medicine, 56(1), 19-‐23.
Barrett, K., & Watson, A. (2005). Physician perspectives on a pilot prescription monitoring program. Journal of Pain and Palliative Care Pharmacotherapy, 19(3), 5-‐13.
Blumenschein, K., Fink, J.L., Freeman, P.R., Kirsh, K.L., Steinke, D.T., & Talbert, J. (2010). Independent evaluation of the impact and effectiveness of the Kentucky All Schedule Prescription Electronic Reporting Program (KASPER). Lexington, Kentucky: Institute for Pharmaceutical Outcomes and Policy, University of Kentucky. Retrieved Sep. 11, 2012, from
Boeuf, O., & Lapeyre-Mestre, M. (2007). Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: Results of OSIAP survey. Drug Safety, 30(3), 265-‐276.
Bohnert, A.S., Valenstein, M., Bair, M.J., Ganoczy, D., McCarthy, J.F., Ilgen, M.A., & Blow, F.C. (2011). Association between opioid prescribing patterns and opioid overdose-related deaths. Journal of the American Medical Association, 305(13), 1315-‐1321.
Buurma, H., Bouvy, M.L., De Smet, P.A., Floor-‐Schreudering, A., Leufkens, H.G., & Egberts, A.C. (2008). Prevalence and determinants of pharmacy shopping behaviour. Journal of Clinical Pharmacy and Therapeutics, 33, 17–23.
Campbell, K.M., Deck, D., & Krupski, A. (2008). Record linkage software in the public domain: a comparison of Link Plus, The Link King, and a ‘basic’ deterministic algorithm. Health Informatics Journal, 14(1), 5-‐15.
Carnevale & Associates and Prescription Drug Monitoring Program Center of Excellence. (2010). Prescription monitoring and prevention: recommendations for increased collaboration. Working paper produced for the Substance Abuse and Mental Health Services Administration.
Centers for Disease Control and Prevention. (2010). Unintentional drug poisoning in the United States. Retrieved Feb. 26, 2012, from www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdf
Coalition Against Insurance Fraud. (2007). Prescription for peril: how insurance fraud finances theft and abuse of addictive prescription drugs. Retrieved Sep. 11, 2012, from www.insurancefraud.org/downloads/drugDiversion.pdf
Cochella, S., & Bateman, K. (2011). Provider detailing: an intervention to decrease prescription opioid deaths in Utah. Pain Medicine, 12(Suppl 2), S73-‐S76. doi: 10.1111/j.1526-‐4637.2011.01125.x.
Curtis, L.H., Stoddard, J., Radeva, J.I., Hutchison, S., Dans, P.E., Wright, A., Woosley, R.L., & Schulman, K.A. (2006). Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Services Research, 41(3 Pt 1), 837-‐855.
DuBose P., Bender A., & Markman, J.W. (2011, June). Rank-‐ordering physicians by opioid abuse and diversion risk. Poster presented at the International Narcotics Research Conference, Hollywood, FL.
Dunn, K.M., Saunders, K.W., Rutter, C.M., Banta-‐Green, C.J., Merrill, J.O., Sullivan, M.D., Weisner, C.M., Silverberg, M.J., Campbell, C.I., Psaty, B.M., & Von Korff, M. (2010). Opioid prescriptions for chronic pain and overdose. Annals of Internal Medicine, 152(2), 85-‐93.
Eadie, J.L. (1990). Policy concerns: benzodiazepine abuse and misuse: New York State’s response. In B.B. Wilford (Ed.), Balancing the Response to Prescription Drug Abuse: Report of a National Symposium on Medicine and Public Policy (pp. 93-‐102). Chicago IL: American Medical Association.
Eadie, J.L. (1993). New York State triplicate prescription program. In J.R. Cooper, D.J. Czechowicz, S.P. Molinari, & R.C. Petersen (Eds.), Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care: NIDA Research Monograph 131 (pp. 176-‐193). Rockville, MD: U.S. Department of Health and Human Services, National Institute on Drug Abuse.
Eadie, J.L. (2010, May). Prescription monitoring programs and law enforcement: an overview. Presentation made at the PDMP/Law Enforcement meeting, Alliance of States with Prescription Monitoring Programs, San Antonio, TX.
Eadie, J.L. (2011, March). Prescription monitoring program roles. Presentation made at the Surgeon General’s Expert Panel on Prescription Drug Abuse in Youth, Washington, DC.
Eadie, J.L. (2011, May). Toward the next generation of PMPs: enhancing prescription monitoring programs’ ability to address the prescription drug abuse epidemic. Presentation made to the U.S. Senate Sub-Committee on Crime and Terrorism, Washington, DC.
Feldman, L., Williams, K.S., Coates, J., & Knox. M. (2011). Awareness and utilization of a prescription monitoring program among physicians. Journal of Pain and Palliative Care Pharmacotherapy, 25(4), 313-‐317.
Fischer, B., Jones, W., Krahn, M., & Rehm, J. (2011). Differences and over-‐time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiology and Drug Safety, 20(12), 1269-1277. doi: 10.1002/pds.2190.
Fisher, J.E., Zhang, Y., Sketris, I., Johnston, G., & Burge, F. (2011). The effect of an educational intervention on meperidine use in Nova Scotia, Canada: a time series analysis. Pharmacoepidemiology and Drug Safety, 21(2), 177-‐183. doi: 10.1002/pds.2259.
Fisher, J.E., Sanyal, C., Frail, D., & Sketris, I. (2011). The intended and unintended consequences of benzodiazepine monitoring programmes: a review of the literature. Journal of Clinical Pharmacy and Therapeutics, 37(1), 7-21. doi: 10.1111/j.1365-‐2710.2011.01245.x.
Fornili, K., & Simoni-‐Wastila, L. (2011). Prescription monitoring programs: striking the balance between medical use and diversion. Journal of Addictions Nursing, 22(1-2), 77-82.
Gilson, A.M., Fishman, S.M., Wilsey, B.L., Casamalhuapa, C., & Baxi, H. (2012). Time series analysis of California's prescription monitoring program: impact on prescribing and multiple provider episodes. Journal of Pain, 13(2), 103-111.
Gomes, T., Mamdani, M., Dhalla, I., Paterson, M., & Juurlink, D. (2011). Opioid dose and drug-related mortality in patients with nonmalignant pain. Archives of Internal Medicine, 171(7), 686-‐691.
Government Accountability Office (GAO). (2011). Medicare Part D: instances of questionable access to prescription drugs. (GAO-12-104T). Washington, DC. Retrieved Sep. 11, 2012, from www.gao.gov/assets/590/585579.pdf
Government Accountability Office (GAO). (2009). Medicaid: fraud and abuse related to controlled substances identified in selected states (GAO-‐09-‐957). Washington, DC. Retrieved Sep. 11, 2012, from www.gao.gov/new.items/d09957.pdf
Hall, A.J., Logan, J.E., Toblin, R.L., Kaplan, J.A., Kraner, J.C., Bixler, D., Crosby, A.E., & Paulozzi, L.J.
(2008). Patterns of abuse among unintentional pharmaceutical overdose fatalities. The Journal of American Medical Association, 300(22), 2613-‐20.
Johnson, E.M., Porucznik, C.A., Anderson, J.W., & Rolfs, R.T. (2011). State-level strategies for reducing prescription drug overdose deaths: Utah's prescription safety program. Pain Medicine, Suppl 2:S66-‐72. doi: 10.1111/j.1526-1637.2011.01126.x.
Joranson, D.E. & Dahl, J.L. (1989). Achieving balance in drug policy: the Wisconsin model. In C.S. Hill, Jr. & W.S. Fields, Advances in Pain Research and Therapy (pp. 197-‐204). New York, NY: Raven Press.
Joranson, D.E., Carrow, G.M., Ryan, K.M., Schaefer, L., Gilson, A.M., Good, P., Eadie, J., Peine, S., & Dahl, J.L. (2002). Pain management and prescription monitoring. The Journal of Pain Symptom Management, 23(3), 231-8.
Katz, N., Houle, B., Fernandez, K.C., Kreiner, P., Thomas, C.P., Kim, M., Carrow, G.M., Audet, A, & Brushwood, D. (2008). Update on prescription monitoring in clinical practice: a survey study of prescription monitoring program administrators. Pain Medicine, 9(5):587-‐94. Epub 2008 Jun 28.
Katz, N., Panas, L., Kim, M., Audet, A.D., Bilansky, A., Eadie, J., Kreiner, P., Paillard, F.C., Thomas, C., & Carrow, G. (2010). Usefulness of prescription monitoring programs for surveillance: analysis of Schedule II opioid prescription data in Massachusetts, 1996-‐2006. Pharmacoepidemiology and Drug Safety, 19(2), 115-‐23.
Kentucky Cabinet for Health and Family Services and Kentucky Injury Prevention and Research Center. (2010). 2010 KASPER satisfaction survey: executive summary. Retrieved Sep. 11, 2012, from chfs.ky.gov/NR/rdonlyres/BDC0DFC9-‐924B-4F11-A10A-5EB17933FDDB/0/2010KASPERSatisfactionSurveyExecutiveSummary.pdf
Kreiner, P. (2011, June). Non-‐medical prescription drug use and market intervention: prescription drug monitoring program data and law enforcement. Presentation made at the National Institutes of Justice Annual Conference, Washington, DC.
Kreiner, P. (2012, April). Geospatial analyses of opioid overdose rates and rates of questionable activity in Massachusetts. Presentation made at the National Prescription Drug Abuse Summit, Orlando, FL.
Lambert, D. (2007). Impact evaluation of Maine’s prescription drug monitoring program. Portland, ME: Muskie School of Public Service, University of Southern Maine. Retrieved Sep. 11, 2012, from webapp.usm.maine.edu/MuskieWebDBfrontend/projectView.action;jsessionid=FAED7067735280
LeMire, S. (2010). Evaluation of the efficacy of the North Dakota prescription drug monitoring program online training. Grand Forks, ND: Bureau of Educational Services and Applied Research (BESAR), University of North Dakota. Retrieved Sep. 11, 1012, from www.nascsa.org/nascsaPMP/PMPnews/NDPDMPtrainingEvaluation.pdf
LeMire, S., Martner, S., & Rising, C. (2012). Advanced practice nurses’ use of prescription drug monitoring program Information. The Journal for Nurse Practitioners, 383-‐405. doi: 10.1016/j.nurpra.2012.02.016
Lipton, B., Laws, C., & Li, L. (2011). Workers compensation prescription drug study: 2011 update, NCCI Research Brief. Boca Raton, FL: National Council on Compensation Insurance Holdings Inc.
Retrieved Sep. 11, 2012, from www.ncci.com/documents/2011_ncci_research_rxdrug_study.pdf
Lohr, K.N. (2004). Rating the strength of scientific evidence: relevance for quality improvement programs. International Journal of Quality Health Care, 16(1), 9-18.
Massachusetts Department of Public Health. (2010, August). Request to Public Health Council for final promulgation of amendments to regulations implementing the Controlled Substances Act, 105 CMR 700.000, concerning the Prescription Monitoring Program. Public Health Advisory Council Meeting, Boston, MA.
Massachusetts Department of Public Health. (2012, February). PDMP Advisory Council presentation. Public Health Advisory Council Meeting, Boston, MA.
Massachusetts Department of Public Health. (2012, April). Presentation made at National Rx Drug Abuse Summit, Washington, DC.
McDonald, D., Hurd, D., Lloyd-‐Kolkin, S., Hamilton, C., Reddy, P., & Adedokun, L. (2004). Prescription monitoring programs: current practices and suggestions for further research on their effectiveness. Cambridge, MA: Abt Associates.
National Alliance for Model State Drug Laws. (2011a). Interstate sharing of prescription monitoring database information. Retrieved June 28, 2012, from namsdl.org/documents/InterstateSharingofPMPInformation10.14.2011.pdf
National Alliance for Model State Drug Laws. (2011b). States that allow practitioners to designate an authorized agent to access the PMP database. Retrieved June 28, 2012, from www.namsdl.org/documents/StatesthatAllowPractitionerstoDesignateanAuthorizedAgenttoAcces
National Alliance for Model State Drug Laws. (2012a). States that require practitioners to register for PMP database. Retrieved June 28, 2012, from www.namsdl.org/documents/StatesthatRequirePractitionerstoRegisterforPMP.pdf
National Alliance for Model State Drug Laws. (2011b). States that require prescribers and/or dispensers to access PMP database in certain circumstances. Retrieved June 28, 2012, from www.namsdl.org/documents/RequirementtoAccess_000.pdf
National Alliance for Model State Drug Laws. (2012c). States that require certain authorized users to undergo training and/or completion of educational courses before accessing PDMP data. Retrieved Sep. 11, 2012, from
Office of National Drug Control Policy. (2011). Epidemic: responding to America’s prescription drug abuse crisis. Washington, DC: Executive Office of the President of the United States. Retrieved Feb. 26, 2012, from www.whitehouse.gov/sites/default/files/ondcp/issues-‐content/prescription-‐
Owens, D.K., Lohr, K.N., Atkins, D., Treadwell, J.R., Reston, J.T., Bass, E.B., Chang, S., & Helfand, M. (2010). AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—agency for healthcare research and quality and the effective health-care program. The Journal of Clinical Epidemiology, 63(5), 513-‐23.
Paulozzi, L.J., & Stier, D.D. (2010). Prescription drug laws, drug overdoses, and drug sales in New York and Pennsylvania. The Journal of Public Health Policy, 31(4), 422-‐32.
Paulozzi, L.J., Kilbourne, E.M., & Desai, H.A. (2011). Prescription drug monitoring programs and death rates from drug overdose. Pain Medicine, 12(5), 747-‐54. doi: 10.1111/j.1526-‐4637.2011.01062.x. Epub 2011 Feb 18.
Paulozzi, L.J. (2011, June). High-‐decile prescribers: all gain, no pain? Presentation made at the 2011 Harold Rogers Prescription Drug Monitoring Program National Meeting, Washington, DC.
Paulozzi, L.J., Kilbourne, E.M., Shah, N.G., Nolte, K.B., Desai, H.A., Landen, M.G., Harvey, W., & Loring, L.D. (2012). A history of being prescribed controlled substances and risk of drug overdose death. Pain Medicine, 13, 87-‐95.
Pauly, V., Frauger, E., Pradel, V., Rouby, F., Berbis, J., Natali, F., Reggio, P., Coudert, H., Micallef, J., & Thirion, X. (2011). Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling High Dosage Buprenorphine abuse. Drug and Alcohol Dependence, 113(1), 29-‐36. Epub 2010 Aug 8.
Payne, S., & Thayer, D. (2009). Epidemiological analysis of the Maine prescription monitoring program (PMP) data. Portland, ME: Muskie School of Public Service, University of Southern Maine. Retrieved Sep. 11, 2012, from muskie.usm.maine.edu/Publications/Maine-‐PMP.pdf
Pearson, S., Soumerai, S., Mah, C., Zhang, F., Simoni-‐Wastilla, L., Salzman, C., Cosler, L., Fanning, T., Gallagher, P., & Ross-‐Degnan, D. (2006). Racial disparities in access after regulatory surveillance of benzodiazepines. Archives of Internal Medicine, 166, 572-‐579.
Peirce, G.L., Smith, M.J., Abate, M.A., & Halverson, J. (2012). Doctor and pharmacy shopping for controlled substances. Medical Care, 50(6), 494-‐500.
Perrone, J., & Nelson, L. (2012). Medication reconciliation for controlled Substances: an “ideal” prescription drug monitoring program. The New England Journal of Medicine, 10.1056/NEJMp1204493.
Pradel, V., Frauger, E., Thirion, X., Ronfle, E., Lapierre, V., Masut, A., Coudert, C., Blin, O., & Micallef, J. (2009). Impact of a prescription monitoring program on doctor-‐shopping for high dosage buprenorphine. Pharmacoepidemiology and Drug Safety, 18(1), 36-‐43.
Prescription Drug Monitoring Program Center of Excellence. (2010). Positive customer identification. Unpublished analysis of state prescription monitoring data.
Prescription Drug Monitoring Program Center of Excellence. (2010). Unpublished analysis of PDMP performance measure data collected by the Bureau of Justice Assistance.
Prescription Drug Monitoring Program Center of Excellence. (2010). Trends in Wyoming PDMP prescription history reporting: evidence for a decrease in doctor shopping? NFF 1.1. Heller School, Brandeis University. Waltham, MA.
Prescription Drug Monitoring Program Center of Excellence. (2011). Unpublished analysis of the Second State PDMP Profiles Survey conducted for the Bureau of Justice Assistance.
Prescription Drug Monitoring Program Center of Excellence. (2011). Staying clear of the law and addiction: Nevada’s Pre-‐Criminal Intervention Program. NFF 2.1. Heller School, Brandeis University. Waltham, MA.
Prescription Drug Monitoring Program Center of Excellence. (2011). Briefing on PDMP effectiveness: PDMPs—an effective tool in curbing the prescription drug abuse epidemic. Heller School, Brandeis University. Waltham, MA.
Prescription Drug Monitoring Program Center of Excellence. (2011). Keeping patients safe: a case study on using prescription monitoring program data in an outpatient addictions treatment setting. NFF 2.2. Heller School, Brandeis University, Waltham, MA.
Prescription Drug Monitoring Program Center of Excellence. (2001).Perspective from Kentucky: using PDMP data in drug diversion investigations. Notes from the Field 2.3. Heller School, Brandeis University. Waltham, MA.
Prescription Drug Monitoring Program Center of Excellence. (2011). Monitoring and changing behavior: the role of PDMP data in Kentucky drug courts. NFF 2.4. Heller School, Brandeis University. Waltham, MA.
Prescription Drug Monitoring Program Center of Excellence. (2011). Nevada’s proactive PDMP: the impact of unsolicited reports. NFF 2.5. Heller School, Brandeis University. Waltham, MA.
Prescription Drug Monitoring Program Center of Excellence. (2011). Drug-related deaths in Virginia: medical examiner use of PDMP data. NFF 2.6. Heller School, Brandeis University. Waltham, MA.
Prescription Drug Monitoring Program Center of Excellence. (2012). Real-time reporting: Oklahoma’s pioneering PDMP. NFF 3.1. Heller School, Brandeis University. Waltham, MA.
Prescription Drug Monitoring Program Center of Excellence. (2012). Project Lazarus: using PDMP data to mobilize and measure community drug abuse prevention. NFF 3.2. Heller School, Brandeis University. Waltham, MA.
Reifler, L.M., Droz, D., Bartelson, B.B., Bailey, J.E., Schnoll, S., & Dart, R.C. (2012). Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Medicine 2012:13, 434–442.
Reisman, R.M., Shenoy, P.J., Atherly, A.J., & Flowers, C.R. (2009). Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring efficacy. Substance Abuse: Research and Treatment. 2009:3, 41-‐51.
Rigg, K.K., March, S.J., & Inciardi, J.A. (2010). Prescription drug abuse and diversion: role of the pain clinic. Journal of Drug Issues. 40(3), 681-‐702.
Rosenblatt, N. (2007). Reducing the diversion of scheduled prescription medications in the Commonwealth of Kentucky: 2006 KASPER Satisfaction Survey: Executive summary. Kentucky Cabinet for Health and Family Services: Frankfort, KY.
Simeone, R. & Holland, L. (2006). An evaluation of prescription drug monitoring programs. Simeone Associates, Inc. Albany, NY. Retrieved on September 11, 2012 from www.simeoneassociates.com/simeone3.pdf
Sorg, M., Labrie, S., & Parker, W. (2009). Analysis and evaluation of participation by prescribers and dispensers in the Maine state prescription monitoring program. Margaret Chase Smith Policy Center, University of Maine. Retrieved on September 11, 2012 from mcspolicycenter.umaine.edu/files/pdf/PMP%20Report%20Final%20Nov09.pdf
Substance Abuse and Mental Health Services Administration, National All Schedules Prescription Electronic Reporting Act Program Grants. (2005). Request for Applications (RFA) No. TI-‐11-‐F1, Catalogue of Federal Domestic Assistance (CFDA) No.: 93.975. p. 10.
Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network. (2010). Highlights of the 2009 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. The DAWN Report. DAWN10-‐1228. Retrieved on September 11, 2012, from store.samhsa.gov/product/Highlights-of-the-2009-Drug-Abuse-Warning-Network-DAWN-Findings-on-Drug-Related-Emergency-Department-Visits/DAWN10-1228
Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set. (2011) Substance abuse treatment admissions for abuse of benzodiazepines. The TEDS Report. TEDS11-0602. Retrieved on September 11, 2012, from store.samhsa.gov/product/Substance-Abuse-Treatment-Admissions-for-Abuse-of-Benzodiazepines/TEDS11-0602
Tufts Health Care Institute Program on Opioid Risk Management. (2011). Advancing safe opioid prescribing through prescriber training and behavior change. Retrieved on September 11, 2012, from www.thci.org/opioid/mar11docs/Prescriber%20Education%20Executive%20Summary%20final.pdf
Twillman, R. (2006). Impact of prescription monitoring programs on prescription patterns and indicators of opioid abuse. Journal of Pain, Supplement. 7(4), S6.
Ulbrich, T.R., Dula, C.A., Green, C.G., Porter, K., & Bennett, M.S. (2010). Factors influencing community pharmacists' enrollment in a state prescription monitoring program. Journal of the American Pharmacists Association. 50(5), 588-‐94.
United States Government Accountability Office (GAO). (2002). Prescription drugs: state monitoring programs provide useful tool to reduce diversion. Washington, D.C. GAO Report GAO-‐02-‐634.
Virginia Department of Health Professions and Virginia State Police. (2004). Prescription monitoring program. Richmond, VA. Retrieved September 11, 2012, from www.dhp.virginia.gov/dhp_programs/pmp/docs/REPORT%20OF%20THE%20PMP.pdf
Virginia Prescription Monitoring Program. (2010). 2010 Statistics. Retrieved September 11, 2012, from www.dhp.virginia.gov/dhp_programs/pmp/docs/ProgramStats/2010PMPStatsDec2010.pdf
Wang, J., & Christo, P.J. (2009). The influence of prescription monitoring programs on chronic pain management. Pain Physician. 12(3), 507-‐515.
White, A.G., Birnbaum, H.G., Schiller, M., Tang, J., & Katz, N.P. (2009). Analytic models to identify patients at risk for prescription opioid abuse. American Journal of Managed Care. 15(12), 897-906.
Whitely, M. (2012, January) Opioids pose major concern for comp stakeholders. Workcompcentral available by subscription at ww3.workcompcentral.com/news/story/id/96a7f1d3df648d6ee72730515354e37em#.UE91-‐ K71GSo
Wilsey, B.L., Fishman, S.M., Gilson, A.M., Casamalhuapa, C., Baxi., H, Zhang, H., & Li, C.S. (2010). Profiling multiple provider prescribing of opioids, benzodiazepines, stimulants, and anorectics. Drug and Alcohol Dependence. 112(1-‐2), 99-106. Prescription Drug Monitoring Programs: An Assessement of the Evidence for Best Practices
Wilsey, B.L., Fishman, S.M., Gilson, A.M., Casamalhuapa, C., Baxi., H, Lin, T.C., & Li, C.S. (2011). An analysis of the number of multiple prescribers for opioids utilizing data from the California Prescription Monitoring Program. Pharmacoepidemiology and Drug Safety. 20(12), 1262-8. doi: 10.1002/pds.2129.